- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06863272
Badanie kliniczne kombinacji leczenia opartego na deruxtecan IFinatamab lub jako monoterapia w leczeniu przerzutowego raka prostaty (MCRPC) (MK-2400-01A/Ideate-Prostate02)
MK-2400-01A Podstawienie: faza 1/2, open-label parasol MK-2400-U01 Protokol w celu oceny bezpieczeństwa i skuteczności raka leczenia opartego na deruxtecan i Ifinatamabu samej deruxtecanu w uczestnikach z metastatycznym kastracją
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Toll Free Number
- Numer telefonu: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lokalizacje studiów
-
-
-
La Rioja, Argentyna, F5300COE
- Rekrutacyjny
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentyna, C1426ANZ
- Rekrutacyjny
- Instituto Alexander Fleming ( Site 0202)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 5411 3221 8900
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australia, 2109
- Rekrutacyjny
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +61 2 9812 2956
-
-
-
-
-
São Paulo, Brazylia, 01221-020
- Rekrutacyjny
- IPITEC ( Site 0275)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +551194322-6006
-
São Paulo, Brazylia, 03102-006
- Rekrutacyjny
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +551144500360
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazylia, 59062-000
- Rekrutacyjny
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
Kontakt:
- Study Coordinator
- Numer telefonu: (84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazylia, 90035-001
- Rekrutacyjny
- Hospital Moinhos de Vento ( Site 0278)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +55 51 3314-3209
-
Porto Alegre, Rio Grande do Sul, Brazylia, 90020-090
- Rekrutacyjny
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +555132148151
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brazylia, 12916-542
- Rekrutacyjny
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +551124901366
-
Ribeirão Preto, São Paulo, Brazylia, 14048900
- Rekrutacyjny
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
Kontakt:
- Study Coordinator
- Numer telefonu: (16) 3963-6487
-
São José do Rio Preto, São Paulo, Brazylia, 15090-000
- Rekrutacyjny
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +55 17 99625-3919
-
São Paulo, São Paulo, Brazylia, 01327-001
- Rekrutacyjny
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 55 11 3549-0009
-
-
-
-
Maule Region
-
Talca, Maule Region, Chile, 3465584
- Rekrutacyjny
- Clinica Universidad Catolica del Maule ( Site 0236)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 56992992913
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 8420383
- Rekrutacyjny
- Bradfordhill ( Site 0231)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +56229490970
-
Santiago, Region M. de Santiago, Chile, 7560908
- Rekrutacyjny
- Centro de Oncología de Precisión ( Site 0241)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +56225189885
-
Santiago, Region M. de Santiago, Chile, 7500921
- Rekrutacyjny
- Fundación Arturo López Pérez ( Site 0232)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Rekrutacyjny
- ONCOCENTRO APYS ( Site 0234)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +56323320850
-
-
-
-
Gironde
-
Bordeaux, Gironde, Francja, 33000
- Rekrutacyjny
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +33556333261
-
-
Nord
-
Lille, Nord, Francja, 59000
- Rekrutacyjny
- Centre Oscar Lambret ( Site 0495)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Francja, 44800
- Rekrutacyjny
- Institut De Cancerologie De L Ouest ( Site 0494)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne, Pyrenees-Atlantiques, Francja, 64100
- Rekrutacyjny
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +33559443762
-
-
Rhone
-
Pierre-Bénite, Rhone, Francja, 69310
- Rekrutacyjny
- centre hospitalier lyon sud ( Site 0497)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 33 4 78 86 43 24
-
-
-
-
-
Madrid, Hiszpania, 28034
- Rekrutacyjny
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34913368263
-
Madrid, Hiszpania, 28041
- Rekrutacyjny
- Hospital Universitario 12 de Octubre ( Site 0622)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34608464547
-
Madrid, Hiszpania, 28040
- Rekrutacyjny
- Hospital Clinico San Carlos ( Site 0618)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34913303546
-
Seville, Hiszpania, 41013
- Rekrutacyjny
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat, Barcelona, Hiszpania, 08908
- Rekrutacyjny
- ICO L Hospitalet ( Site 0617)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34932607744
-
-
-
-
Gelderland
-
Ede, Gelderland, Holandia, 6716 RP
- Rekrutacyjny
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +31 318 435499
-
Nijmegen, Gelderland, Holandia, 6525 GA
- Rekrutacyjny
- UMC St. Radboud ( Site 0679)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +31 24 361 1111
-
-
Provincie Friesland
-
Drachten, Provincie Friesland, Holandia, 9202 NN
- Rekrutacyjny
- Nij Smellinghe ( Site 0684)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 0512 588 888
-
-
-
-
-
Dublin, Irlandia, D09 V2N0
- Rekrutacyjny
- Beaumont Hospital, Dublin ( Site 0465)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 0035318092010
-
Dublin, Irlandia, D24 NR0A
- Rekrutacyjny
- Tallaght University Hospital ( Site 0462)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 0035314144209
-
-
Dublin
-
Dublin, Dublin, Irlandia, D04 T6F4
- Rekrutacyjny
- St Vincent's University Hospital ( Site 0463)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +353 1 221 4982
-
-
-
-
-
Haifa, Izrael, 3109601
- Rekrutacyjny
- Rambam Health Care Campus ( Site 0400)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 972(47776234)
-
Jerusalem, Izrael, 9112001
- Rekrutacyjny
- Hadassah Medical Center ( Site 0404)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +97226777333
-
Petah Tikva, Izrael, 4941492
- Rekrutacyjny
- Rabin Medical Center ( Site 0402)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +972544594048
-
Ramat Gan, Izrael, 5265601
- Rekrutacyjny
- Sheba Medical Center ( Site 0401)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +97235303030
-
Tel Aviv, Izrael, 6423906
- Rekrutacyjny
- Sourasky Medical Center ( Site 0403)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +97236947832
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Rekrutacyjny
- BC Cancer - Vancouver Center ( Site 0103)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 6048776000
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutacyjny
- Sunnybrook Research Institute ( Site 0109)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 4164806100
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutacyjny
- Princess Margaret Cancer Centre ( Site 0102)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 4169464501
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutacyjny
- Jewish General Hospital ( Site 0108)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 5143408110
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutacyjny
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 8197802222
-
-
-
-
-
Seoul, Korea Południowa, 06351
- Rekrutacyjny
- Samsung Medical Center ( Site 0926)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82234103459
-
Seoul, Korea Południowa, 03722
- Aktywny, nie rekrutujący
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu, Seoul, Korea Południowa, 05505
- Rekrutacyjny
- Asan Medical Center ( Site 0925)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82230105977
-
-
-
-
-
Hamburg, Niemcy, 20246
- Rekrutacyjny
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Niemcy, 69120
- Rekrutacyjny
- NCT ( Site 0528)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 00496221566857
-
Ulm, Baden-Wurttemberg, Niemcy, 89081
- Rekrutacyjny
- Universitaetsklinikum Ulm. ( Site 0530)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +4973150058188
-
-
Thuringia
-
Jena, Thuringia, Niemcy, 07747
- Rekrutacyjny
- Universitaetsklinikum Jena ( Site 0525)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +49-3641-9-329901
-
-
-
-
-
Auckland, Nowa Zelandia, 1023
- Rekrutacyjny
- Auckland City Hospital ( Site 0831)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +6493074949
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polska, 60-355
- Rekrutacyjny
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polska, 02-781
- Rekrutacyjny
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polska, 80-214
- Rekrutacyjny
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Polska, 75-581
- Rekrutacyjny
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +48943488930
-
-
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90095
- Rekrutacyjny
- UCLA Hematology & Oncology ( Site 0003)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 310-829-5471
-
Orange, California, Stany Zjednoczone, 92868
- Rekrutacyjny
- University of California-Irvine Medical Center ( Site 0016)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 714-456-5153
-
San Francisco, California, Stany Zjednoczone, 94158
- Rekrutacyjny
- UCSF Medical Center at Mission Bay ( Site 0034)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 415-502-2097
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 202-877-3061
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- University of Michigan ( Site 0021)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 734-936-4000
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 347-798-8620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- Rekrutacyjny
- UPMC Hillman Cancer Center ( Site 0014)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 412-647-2811
-
-
Tennessee
-
Germantown, Tennessee, Stany Zjednoczone, 38138
- Rekrutacyjny
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 901-683-0055
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- Rekrutacyjny
- Fred Hutchinson Cancer Center ( Site 0013)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 206-288-1111
-
-
-
-
-
Taichung, Tajwan, 40705
- Rekrutacyjny
- Taichung Veterans General Hospital ( Site 0902)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +886423592525
-
Taipei, Tajwan, 11217
- Rekrutacyjny
- Taipei Veterans General Hospital ( Site 0901)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +886228712121
-
-
-
-
-
Adana, Turcja (Türkiye), 01250
- Rekrutacyjny
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +903223271274
-
Ankara, Turcja (Türkiye), 06230
- Rekrutacyjny
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +90 312 305 50 00
-
Ankara, Turcja (Türkiye), 06800
- Rekrutacyjny
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +903125526000
-
Ankara, Turcja (Türkiye), 06620
- Rekrutacyjny
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +903122126040
-
Istanbul, Turcja (Türkiye), 34010
- Rekrutacyjny
- Koç Üniversitesi Hastanesi ( Site 0656)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +905369410661
-
Istanbul, Turcja (Türkiye), 34098
- Rekrutacyjny
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +902124143000
-
Rize, Turcja (Türkiye), 53020
- Rekrutacyjny
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +904642130491
-
-
-
-
-
Brescia, Włochy, 25123
- Aktywny, nie rekrutujący
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan, Włochy, 20133
- Rekrutacyjny
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +390223904449
-
Naples, Włochy, 80131
- Rekrutacyjny
- A.O.U. Federico II di Napoli ( Site 0435)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +390817463660
-
Roma, Włochy, 00168
- Rekrutacyjny
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +390630155202
-
-
Torino
-
Orbassano, Torino, Włochy, 10143
- Rekrutacyjny
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 00390119026534
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Zjednoczone Królestwo, CB2 2QQ
- Rekrutacyjny
- Addenbrooke's Hospital ( Site 0747)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 00441223216083
-
-
London, City of
-
London, London, City of, Zjednoczone Królestwo, NW3 2QG
- Rekrutacyjny
- Royal Free Hospital ( Site 0743)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 00442077940500/2237
-
London, London, City of, Zjednoczone Królestwo, EC1A 7BE
- Rekrutacyjny
- St Bartholomew's Hospital ( Site 0749)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 00442073777000
-
-
Surrey
-
London, Surrey, Zjednoczone Królestwo, SM3 5PT
- Rekrutacyjny
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 0203 437 3500
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
Eksperymentalny: Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
Inne nazwy:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
Eksperymentalny: I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Inne nazwy:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
Inne nazwy:
|
|
Eksperymentalny: I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Inne nazwy:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Ramy czasowe: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Ramy czasowe: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Ramy czasowe: Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Ramy czasowe: Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Ramy czasowe: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Ramy czasowe: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Ramy czasowe: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
Ramy czasowe: Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
Ramy czasowe: Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
Ramy czasowe: Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
Ramy czasowe: Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Ramy czasowe: Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
Ramy czasowe: Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Procesy patologiczne
- Nowotwory narządów płciowych, mężczyzna
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby narządów płciowych, mężczyzna
- Choroby prostaty
- Choroby układu moczowo-płciowego u mężczyzn
- Procesy Nowotworowe
- Stany patologiczne, oznaki i objawy
- Nowotwory prostaty
- Przerzuty nowotworu
- Nowotwory prostaty, oporne na kastrację
- Organiczne chemikalia
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Taksoidy
- Cyklodekan
- Diterpenes
- Docetaksel
- abiraterone
- enzalutamid
Inne numery identyfikacyjne badania
- 2400-01A
- MK-2400-01A (Inny identyfikator: MSD)
- U1111-1310-5406 (Identyfikator rejestru: UTN)
- IDeate-Prostate02 (Inny identyfikator: MSD)
- 2024-516036-94-00 (Identyfikator rejestru: EU CT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .